Premium
A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2‐Positive Breast Cancer Cells
Author(s) -
Gray Melissa A.,
Tao Ran N.,
DePorter Sandra M.,
Spiegel David A.,
McNaughton Brian R.
Publication year - 2016
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.201500591
Subject(s) - antibody , cytotoxicity , cancer research , breast cancer , cancer cell , chemistry , cancer , immunotherapy , cancer immunotherapy , biology , immunology , immune system , biochemistry , in vitro , genetics
We report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti‐dinitrophenyl (anti‐DNP) antibodies to the surface of HER2‐positive breast cancer cells, resulting in their targeted destruction by antibody‐dependent cellular cytotoxicity. As nanobodies are relatively easy to express, stable, can be humanized, and can be evolved to potently and selectively bind virtually any disease‐relevant cell surface receptor, we anticipate broad utility of this therapeutic strategy.